ClinVar Miner

Submissions for variant NM_000102.4(CYP17A1):c.286C>T (p.Arg96Trp)

gnomAD frequency: 0.00006  dbSNP: rs104894138
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000255053 SCV000321538 pathogenic not provided 2023-03-24 criteria provided, single submitter clinical testing Published functional studies demonstrate a damaging effect resulting in almost complete loss of enzyme activity (Laflamme et al., 1996; Sahakitrungruang et al., 2009); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 14671162, 12573489, 19470621, 21340163, 8550762, 31589614, 25697092, 30229581, 29255217, 27271787, 33547012, 29144824, 24485502, 31034465, Mohnach[CaseReport]2018)
Genetic Services Laboratory, University of Chicago RCV000501502 SCV000594286 pathogenic Deficiency of steroid 17-alpha-monooxygenase 2016-09-26 criteria provided, single submitter clinical testing
Fulgent Genetics, Fulgent Genetics RCV000501502 SCV000893835 pathogenic Deficiency of steroid 17-alpha-monooxygenase 2021-08-17 criteria provided, single submitter clinical testing
Invitae RCV000255053 SCV001415980 pathogenic not provided 2024-01-22 criteria provided, single submitter clinical testing This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 96 of the CYP17A1 protein (p.Arg96Trp). This variant is present in population databases (rs104894138, gnomAD 0.006%). This missense change has been observed in individuals with congenital adrenal hyperplasia (PMID: 8550762, 21340163, 28008861). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 1785). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CYP17A1 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects CYP17A1 function (PMID: 8550762, 10720067). This variant disrupts the p.Arg96 amino acid residue in CYP17A1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 16569739, 21846181, 23291414, 23466679, 26543560, 28008861). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV003114170 SCV003800630 pathogenic Congenital adrenal hyperplasia 2023-01-30 criteria provided, single submitter clinical testing Variant summary: CYP17A1 c.286C>T (p.Arg96Trp) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2.8e-05 in 251326 control chromosomes (gnomAD). c.286C>T has been reported in the literature in multiple individuals affected with Congenital Adrenal Hyperplasia/17 alpha-hydroxylase/17,20-lyase deficiency (e.g. Laflamme_1996, Biason-Lauber_2000, Costenaro_2010). These data indicate that the variant is very likely to be associated with disease. Experimental studies examining the effect of the variant on protein function have shown that it results in an enzyme activity of approximately 10%-30% of the normal WT protein (e.g. Laflamme_1996, Biason-Lauber_2000). Five submitters have provided clinical-significance assessments for this variant to ClinVar after 2014 and all classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Baylor Genetics RCV000501502 SCV004215398 pathogenic Deficiency of steroid 17-alpha-monooxygenase 2023-08-23 criteria provided, single submitter clinical testing
OMIM RCV000001858 SCV000022014 pathogenic 17-alpha-hydroxylase/17,20-lyase deficiency, combined complete 2003-12-01 no assertion criteria provided literature only
Natera, Inc. RCV000501502 SCV002091218 pathogenic Deficiency of steroid 17-alpha-monooxygenase 2020-09-22 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.